Seoulin Bioscience Co.Ltd (038070) — Free Cash Flow Generation Index
Seoulin Bioscience Co.Ltd (038070) has a Free Cash Flow Generation Index of 0.98x as of December 2025. Free cash flow of ₩620.87 Million represents 1% of operating cash flow (₩631.76 Million). Read Seoulin Bioscience Co.Ltd total liabilities for a breakdown of total debt and financial obligations.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Seoulin Bioscience Co.Ltd Free Cash Flow Generation Index (2013–2025)
Historical FCF Generation Index trend for Seoulin Bioscience Co.Ltd across 11 annual periods. Explore Seoulin Bioscience Co.Ltd capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Annual Free Cash Flow Generation for Seoulin Bioscience Co.Ltd (2013–2025)
Year-by-year Free Cash Flow Generation Index for Seoulin Bioscience Co.Ltd. For the full company profile including market capitalisation, see Seoulin Bioscience Co.Ltd (038070) market capitalisation.
| Year | FCG Index | Free Cash Flow (KRW) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.89x | ₩4.25 Billion | ₩4.76 Billion | ₩507.47 Million | ▲ +2004.7% |
| 2023 | -0.05x | ₩-43.65 Million | ₩930.57 Million | ₩974.21 Million | ▼ -105.8% |
| 2021 | 0.81x | ₩7.25 Billion | ₩8.92 Billion | ₩1.67 Billion | ▲ +9.2% |
| 2020 | 0.74x | ₩2.74 Billion | ₩3.68 Billion | ₩401.34 Million | ▼ -28.2% |
| 2019 | 1.04x | ₩7.59 Billion | ₩7.32 Billion | ₩269.29 Million | ▼ -5.6% |
| 2018 | 1.10x | ₩4.58 Billion | ₩4.17 Billion | ₩408.02 Million | ▼ -85.8% |
| 2017 | 7.71x | ₩10.03 Billion | ₩1.30 Billion | ₩8.73 Billion | ▲ +113.0% |
| 2016 | 3.62x | ₩9.97 Billion | ₩2.76 Billion | ₩7.21 Billion | ▲ +89.5% |
| 2015 | 1.91x | ₩7.86 Billion | ₩4.12 Billion | ₩3.74 Billion | ▲ +49.4% |
| 2014 | 1.28x | ₩3.50 Billion | ₩2.74 Billion | ₩761.57 Million | ▲ +26.4% |
| 2013 | 1.01x | ₩4.99 Billion | ₩4.94 Billion | ₩55.65 Million | — |